# Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients

> **NCT03016884** · PHASE4 · UNKNOWN · sponsor: **HaEmek Medical Center, Israel** · enrollment: 87 (actual)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** Zostavax vaccine

## Key facts

- **NCT ID:** NCT03016884
- **Lead sponsor:** HaEmek Medical Center, Israel
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-01
- **Primary completion:** 2019-09
- **Final completion:** 2020-07
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2020-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03016884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03016884, "Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03016884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*